Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
The Interim Analysis Showed Complete Clinical Clearance of More Than Sixty (60%) Percent The Interim Analysis Showed Complete Clinical Clearance of More Than Sixty (60%) Percent
Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
The Interim Analysis Showed Complete Clinical Clearance of More than Sixty (60%) Percent Philadelphia, Pennsylvania--(Newsfile Corp. - March 6, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce a positively trending interim analysis for SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin (BCC).
Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
The Clinical Study is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE Philadelphia, Pennsylvania--(Newsfile Corp. - February 27, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce that it has submitted a clinical design (SKNJCT-004) to UAE DOH to non-invasively treat BCC of the skin.
Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
The Clinical Study is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE The Clinical Study is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE
Boise Cascade Q4 Earnings Miss, Sales Top, Adjusted EBITDA Down Y/Y
BCC's fourth-quarter 2024 results reflect unfavorable sales price trends. Dive in to learn more about the quarterly performance.
Boise Cascade Promotes Nathan Sikes to Senior Vice President of Western Operations for Building Materials Distribution Division
BOISE, Idaho--(BUSINESS WIRE)--Boise Cascade Company (Boise Cascade) (NYSE: BCC) announced today that Nathan Sikes will be the new Senior Vice President of Western Operations for their Building Materials Distribution (BMD) division, effective February 24, 2025. In this role, Nathan will be responsible for BMD's facilities and door shops located in the Western and Pacific Regions. Since joining Boise Cascade in 2006, Nathan has held a series of key roles and progressive leadership positions in t.
Boise Cascade Company, Inc. (BCC) Q4 2024 Earnings Call Transcript
Boise Cascade Company, Inc. (NYSE:BCC ) Q4 2024 Earnings Conference Call February 21, 2025 11:00 AM ET Company Participants Chris Forrey - VP, Finance & IR Nathan Jorgensen - CEO & Director Kelly Hibbs - SVP, CFO, Principal Financial & Accounting Officer and Treasurer Jeff Strom - COO Conference Call Participants Kurt Yinger - D.A. Davidson Susan Maklari - Goldman Sachs Mike Roxland - Truist Securities George Staphos - Bank of America Merrill Lynch Ketan Mamtora - BMO Capital Markets Operator Good morning.
Boise Cascade (BCC) Q4 Earnings Lag Estimates
Boise Cascade (BCC) came out with quarterly earnings of $1.78 per share, missing the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $2.44 per share a year ago.
Boise Cascade Company Reports Fourth Quarter and Full Year 2024 Results
BOISE, Idaho--(BUSINESS WIRE)--Boise Cascade Company ("Boise Cascade," the "Company," "we," or "our") (NYSE: BCC) today reported fourth quarter net income of $68.9 million, or $1.78 per share, on sales of $1.6 billion. For the full year 2024, Boise Cascade reported net income of $376.4 million, or $9.57 per share, on sales of $6.7 billion. For 2023 comparative results, see the table below. “As we close out 2024, I first want to express my gratitude to our associates as they have shown commitmen.
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
The company is on track to complete the interim data analysis before the end of Q1 2025 and to submit the findings to the U.S. Food And Drug Administration (FDA) The company is on track to complete the interim data analysis before the end of Q1 2025 and to submit the findings to the U.S. Food And Drug Administration (FDA)
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
The Company Is on Track to Complete the Interim Data Analysis Before the End of Q1 2025 and to Submit the Findings to the U.S. Food and Drug Administration (FDA) Philadelphia, Pennsylvania--(Newsfile Corp. - February 14, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003), which is currently underway in nine (9) clinical sites in United States, has now randomized more than 50% of the 60 patients expected to be enrolled in the study.
Boise Cascade Promotes Joanna (Jo) Barney to Executive Vice President of Building Materials Distribution
BOISE, Idaho--(BUSINESS WIRE)--Boise Cascade Company (Boise Cascade) (NYSE: BCC) announced today that Joanna (Jo) Barney will be the new Executive Vice President of their Building Materials Distribution (BMD) division, effective February 17, 2025. In this role, Jo will oversee the Company's 40+ distribution facilities, including millwork and door shops, across the U.S. Jo joined Boise Cascade in 2005. Prior to this promotion, Jo was the Senior Vice President of BMD Western Operations. Before th.
